Here, we demonstrate that genetic or therapeutic targeting of the PREX2/RAC1/p110β pathway can substantially enhance responses to MAPK targeting in BRAF-mutant melanoma both in vitro and in vivo, presumably through suppression of AKT/mTOR driven cell-cycle progression (Fig. 5E). The gene discussed is MTOR; the disease is melanoma.